Reata Pharmaceuticals Inc (NASDAQ:RETA) major shareholder James W. Traweek, Jr. purchased 27,200 shares of the firm’s stock in a transaction that occurred on Thursday, December 28th. The stock was bought at an average cost of $25.93 per share, for a total transaction of $705,296.00. Following the purchase, the insider now owns 35 shares in the company, valued at $907.55. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Reata Pharmaceuticals Inc (NASDAQ RETA) traded down $0.53 during trading on Friday, reaching $28.31. The company’s stock had a trading volume of 90,200 shares, compared to its average volume of 151,375. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of -0.15. The firm has a market capitalization of $739.30 and a price-to-earnings ratio of -19.39. Reata Pharmaceuticals Inc has a one year low of $19.48 and a one year high of $40.88.
Reata Pharmaceuticals (NASDAQ:RETA) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.11). The business had revenue of $12.60 million during the quarter, compared to the consensus estimate of $12.54 million. The company’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts forecast that Reata Pharmaceuticals Inc will post -1.91 EPS for the current year.
Several brokerages recently commented on RETA. Robert W. Baird reaffirmed a “buy” rating and issued a $47.00 price target on shares of Reata Pharmaceuticals in a research note on Tuesday, October 24th. Zacks Investment Research raised Reata Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 24th. ValuEngine lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Jefferies Group reaffirmed a “buy” rating and issued a $44.00 price target on shares of Reata Pharmaceuticals in a research note on Friday, October 6th. Finally, Cowen reaffirmed a “buy” rating on shares of Reata Pharmaceuticals in a research note on Thursday, December 14th. Three investment analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $54.71.
A number of institutional investors have recently bought and sold shares of the business. Crestline Management LP acquired a new position in Reata Pharmaceuticals in the third quarter worth $1,880,000. First Allied Advisory Services Inc. bought a new stake in shares of Reata Pharmaceuticals during the third quarter worth $203,000. Alyeska Investment Group L.P. bought a new stake in shares of Reata Pharmaceuticals during the third quarter worth $2,832,000. California State Teachers Retirement System raised its position in shares of Reata Pharmaceuticals by 21.2% during the third quarter. California State Teachers Retirement System now owns 18,325 shares of the company’s stock worth $570,000 after acquiring an additional 3,200 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its position in shares of Reata Pharmaceuticals by 83.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 49,828 shares of the company’s stock worth $1,550,000 after acquiring an additional 22,628 shares during the last quarter. 29.58% of the stock is currently owned by institutional investors.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.